Gate2Brain
  • Home
  • Company
  • Team
  • Technology
  • Investors
  • News & Media
  • Contact
  • Menu Menu

Gate2Brain co-signs its first article in ACS Publications under the title “Amphiphilic Polymeric Nanoparticles Modified with Protease-Resistant Peptide Shuttle for the Delivery of SN-38 in Diffuse Intrinsic Pontine Glioma”

News
Gate2Brain

Alexandra Bukchin, Macarena Sanchez-Navarro, Adam Carrera, Claudia Resa-Pares, Helena Castillo-Ecija, Leire Balaguer-Lluna, Meritxell Teixidó, Nagore G. Olaciregui, Ernest Giralt, Angel M. Carcaboso, Alejandro Sosnik

Abstract

Diffuse intrinsic pontine glioma (DIPG) is a chemo-resistant, incurable pediatric tumor of the central nervous system (CNS). The blood–brain barrier (BBB) remains intact in the course of the disease, preventing drugs from entering the brain and resulting in therapeutic failure. The topoisomerase I inhibitor SN-38 shows strong anticancer activity in a patient-derived DIPG cell line in vitro, though a low CNS bioavailability and anti-DIPG efficacy in vivo. In this work, we produced SN-38-loaded

polymeric nanoparticles of an amphiphilic chitosan (CS)-g-poly (methyl methacrylate)-poly (acrylic acid) copolymer that were surface-modified with a peptide shuttle that improves transport across the BBB. Drug-loaded nanoparticles displayed a size of ∼200 nm (intensity distribution) and a potential of +16 mV. The cytocompatibility and endocytosis assayed in DIPG cells (both attached and in suspension) indicated that the nanoparticles are compatible and mainly internalized by clathrin-mediated endocytosis and that the anticancer activity of SN-38 is preserved after nanoencapsulation. In addition, a tandem permeability/anticancer activity study utilizing a coculture model of BBB endothelial cells and DIPG cell spheroids demonstrated that the modified nanoparticles cross a BBB endothelial cell monolayer to a higher extent than the unmodified counterparts and are taken up by DIPG cells. After 72 h of exposure, both SN-38-loaded nanoparticles killed ∼84-88% of the DIPG cells in suspension, indicating that they reach a concentration above the inhibitory concentration 50 of the drug. Finally, the brain accumulation of the drug-loaded nanoparticles upon intravenous injection to Hsd:ICR mice was preliminarily characterized by light sheet fluorescence microscopy. As opposed to unmodified SN-38-loaded nanoparticles, the modified counterparts bind the brain blood vessels and accumulate in the cerebral parenchyma to a large extent.

These results confirm the potential of this nanotechnology platform to deliver anticancer agents to the brain in DIPG and other brain tumors with fully conserved BBB.

 


Source:
ACS Publications
https://pubs.acs.org/doi/pdf/10.1021/acsanm.0c02888

January 14, 2021/by Susana Meneses
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://gate2brain.com/wp-content/uploads/2021/01/News.jpg 648 1329 Susana Meneses https://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.png Susana Meneses2021-01-14 15:22:392021-03-17 16:02:34Gate2Brain co-signs its first article in ACS Publications under the title “Amphiphilic Polymeric Nanoparticles Modified with Protease-Resistant Peptide Shuttle for the Delivery of SN-38 in Diffuse Intrinsic Pontine Glioma”

CATEGORIES

  • News
  • Press releases

Press releases

  • Gate2BrainBStartup of Banco de Sabadell invests in Gate2Brain biotechDecember 29, 2020 - 13:17
  • Gate2BrainGate2Brain seeks up to 3 million euros to reach the clinical trialNovember 24, 2020 - 17:14
  • Gate2BrainThe Mind the Gap program of Botín Foundation invests 1.5 million euros in three new biotech startupsJuly 9, 2020 - 17:23
  • Gate2BrainLaunch of Gate2Brain, the “key” to transporting drugs into the brain and improving their effectivenessJuly 9, 2020 - 15:52

SOCIAL

  • linkedin

RSS RSS Ciencia

  • Call now open for healthtech projects for CRAASH Barcelona 2021 April 8, 2021 biocat
  • Biocat and Barcelona Health Hub sign partnership agreement to promote the ecosystem April 1, 2021 biocat
  • HIGHLIGHT: Historic new record investments in the BioRegion, advancements in research, vaccines, new funds and innovation projects March 25, 2021 biocat
  • How the pandemic has accelerated some startups in the BioRegion March 24, 2021 biocat
  • Biocat, recognized as United Kingdom’s best Spanish business partner March 24, 2021 biocat
  • The "top invested startups 2020" of the BioRegion at BIO-Europe Spring Virtual March 24, 2021 biocat
  • Investment in health startups in Catalonia doubles in just two years, to over €200 million in 2020 March 23, 2021 biocat
  • New call for Boost4Health internationalization vouchers open now February 25, 2021 biocat
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

  • linkedin
© Copyright –Edisenius
  • Privacy Policy
  • Legal Notice
  • Cookie Policy
BStartup of Banco de Sabadell invests in Gate2Brain biotech Gate2Brain Round Table in 100tífiques “Public Research and Research at Large Corpor...
Scroll to top